Skip to main content
ALUR
OTC Industrial Applications And Services

Allurion Technologies Delisted from NYSE, Now Trading OTCID; Company Appeals and Plans Relisting

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.36
Mkt Cap
$4.421M
52W Low
$0.23
52W High
$4.18
52W Position info
57% above low
Off High info
91% below high
Rel. Volume
Market data snapshot near publication time

ALUR sits 57% above its 52-week low of $0.23.

Summary

Allurion Technologies has been delisted from the NYSE and its shares are now trading on the OTCID Market, following non-compliance with market capitalization rules; the company is appealing the decision and has a plan to relist.


Key Events · Corporate Governance and Compliance · ALUR

  • NYSE Delisting Confirmed

    On March 6, 2026, the NYSE notified Allurion Technologies of its determination to delist the company's common stock and warrants due to non-compliance with the $15 million average global market capitalization rule.

  • Trading Suspended and Moved to OTCID

    Trading on the NYSE was suspended after market close on March 6, 2026, with the common stock now trading on the OTCID Market.

  • Company Appeals Delisting

    Allurion has appealed the NYSE's delisting determination and intends to apply to list on a higher-tier market operated by the OTC Market Group, Inc. or NYSE American.

  • Plan to Regain Compliance

    The company is executing a detailed plan, catalyzed by recent FDA approval, to strengthen its balance sheet and fund commercialization, aiming to regain compliance with NYSE standards or relist on NYSE American.


Analysis · ALUR · Industrial Applications And Services

This 8-K confirms Allurion Technologies' delisting from the New York Stock Exchange (NYSE) due to failing to maintain the minimum $15 million average global market capitalization. Trading in the company's common stock and warrants was suspended on March 6, 2026, and has transitioned to the OTCID Market. While the company has appealed the NYSE's decision and is executing a plan, including leveraging a recent FDA approval, to regain compliance or relist on NYSE American or a higher OTC tier, the immediate impact is a significant reduction in liquidity and investor visibility. This event signals severe financial distress and poses substantial risks to shareholders.

At the time of this filing, ALUR was trading at $0.36 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $4.4M. The 52-week trading range was $0.23 to $4.18. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ALUR - Latest Insights

ALUR
May 15, 2026, 4:38 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.851
Real-time Price: $0.580 info
Change: Reverse Stock Split info
Market Cap: $8.704M info
ALUR
May 08, 2026, 12:29 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.686
Real-time Price: $0.580 info
Change: Reverse Stock Split info
Market Cap: $8.704M info
ALUR
Apr 20, 2026, 8:37 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.800
Real-time Price: $0.580 info
Change: Reverse Stock Split info
Market Cap: $8.704M info
ALUR
Mar 30, 2026, 8:30 AM EDT
Filing Type: 10-K
Importance Score:
10
Price at Filing: $0.7746
Real-time Price: $0.580 info
Change: Reverse Stock Split info
Market Cap: $8.704M info
ALUR
Mar 02, 2026, 9:18 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.05
Real-time Price: $0.580 info
Change: Reverse Stock Split info
Market Cap: $8.704M info